M. Udvardy

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 152 citations · Full text

Lymphoid Neoplasia, End-of-induction Pet Response, Medicine +7

New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort

Mária Papp, I Altorjay, Nir Dotan et al. · The American Journal of Gastroenterology · 2008 · 146 citations

Complement activation in thrombotic thrombocytopenic purpura

Marienn Réti, Péter Farkas, Dorottya Csuka et al. · Journal of Thrombosis and Haemostasis · 2012 · 134 citations · Full text

Thrombopoiesis, Thrombosis, Complement System +8

Shielding of the A1 Domain by the D′D3 Domains of von Willebrand Factor Modulates Its Interaction with Platelet Glycoprotein Ib-IX-V

Hans Ulrichts, M. Udvardy, Peter J. Lenting et al. · Journal of Biological Chemistry · 2005 · 133 citations · Full text

Immunology, Immune System, Inflammation +18

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13